89Bio Inc (ETNB)

$18.23 0.00 (0.00%)

16:00 EDT ETNB Stock Quote Delayed 30 Minutes

Why Is 89bio (ETNB) Stock Up 34% Today?

By William White, InvestorPlace Writer Mar 22, 2023

89bio (ETNB) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial of pegozafermin.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Volume:

Previous Close -

Market Cap 1.33B

PE Ratio -6.91

EPS -2.64

Volume (Avg. Vol.)

Day's Range -

52-Week Range $2.75 - $18.92

Dividend & Yield N/A (N/A)

ETNB Stock Predictions, Articles, and 89Bio Inc News

From the Web

(NASDAQ:ETNB)

From Seeking Alpha May 4, 2023

89bio press release (ETNB): Q1 GAAP EPS of -$0.54 in-line. As of March 31, 2023, 89bio had cash, cash equivalents, and short-term investments totaling $480.9 million.

3 Biotech Buyout Targets to Watch

From The Motley Fool Apr 29, 2023

The trio all have late-stage therapies with blockbuster potential.

Why Shares of 89bio Soared This Week

From The Motley Fool Mar 24, 2023

The company released positive results for its lead therapy.

89bio prices $275M stock offering (NASDAQ:ETNB)

From Seeking Alpha Mar 24, 2023

89bio (ETNB) has priced an underwritten public offering of 16,923,077 shares of its common stock at $16.25/share.In addition, the underwriters have been granted a 30-day option to...

ETNB stock jumps on topline data for NASH candidate (NASDAQ:ETNB)

From Seeking Alpha Mar 22, 2023

89bio (ETNB) added ~47% on Wednesday after announcing topline data from its Phase 2b ENLIVEN trial for pegozafermin in nonalcoholic steatohepatitis ((NASH)). Read the full story here.

89bio GAAP EPS of -$0.48 beats by $0.22 (NASDAQ:ETNB)

From Seeking Alpha Mar 10, 2023

89bio press release (ETNB): Q4 GAAP EPS of -$0.48 beats by $0.22.As of December 31, 2022, 89bio had cash, cash equivalents, and short-term investments totaling $188.2 million compared...